Welcome to our dedicated page for Medifast news (Ticker: MED), a resource for investors and traders seeking the latest updates and insights on Medifast stock.
Medifast, Inc. reports developments as a metabolic health and wellness company built around the OPTAVIA science-backed, coach-guided lifestyle system. Its updates center on revenue trends, gross margin, active earning coaches, coach productivity and the company's shift toward metabolic health amid changes in weight-loss demand and GLP-1 medication adoption.
Recurring company news also covers OPTAVIA program evidence, nutrition and habit-creation offerings, HSA/FSA reimbursement availability on select insurance plans, independent coach community initiatives, media content tied to metabolic health, and governance matters such as board nominations and stockholder cooperation agreements.
Medifast (NYSE: MED) reported Q1 2026 results for the quarter ended March 31, 2026. Revenue was $76.0 million, down 34.3% YoY; independent active earning coaches totaled 14,000, down 44.9% YoY. Net loss was $2.1 million ($0.19 per diluted share). Cash, cash equivalents, and investment securities were $168.9 million with no debt. Management noted higher revenue per coach and continued transformation toward metabolic health; full-year 2026 revenue guidance is $270M–$300M with loss per share guidance of $1.55–$2.75.
Medifast (NYSE: MED) will announce financial results for the quarter ended March 31, 2026 on Monday, May 4, 2026 after market close. The company will host a live conference call at 4:30 p.m. ET on May 4, 2026 to discuss results.
Company participants include Dan Chard (CEO), Nick Johnson (President), and Jim Maloney (CFO). The call will be webcast on the investor relations website and archived online through August 4, 2026. Telephone dial-in and a telephonic playback (May 4–11, 2026) are available with access code 13759893.
Medifast (NYSE: MED) entered a Cooperation Agreement with Steamboat Capital, which beneficially owns above 5% of outstanding shares, and agreed to nominate Parsa Kiai and Jeff Rose as independent director candidates for the May 19, 2026 annual meeting.
Medifast’s board determined directors Jeffrey Brown and Michael Hoer will not stand for reelection. CEO Dan Chard will step down on June 1, 2026, with President Nicholas Johnson expected to succeed him. The agreement includes customary standstill and voting provisions through the 2027 annual meeting.
Medifast (NYSE: MED) announced that OPTAVIA’s metabolic health system is now eligible for reimbursement on select insurance plans using HSA/FSA funds, potentially letting clients save up to 40% on program costs.
The company cites Metabolic Synchronization science and a clinical result showing 98% lean mass retained and a 14% reduction in visceral adiposity at 16 weeks, and plans a new product system launch in 2026.
Medifast (NYSE: MED) reported Q4 2025 revenue of $75.1M and full-year 2025 revenue of $385.8M, with Q4 net loss of $18.1M and full-year net loss of $18.7M. Cash and investment securities totaled $167.3M with no debt. Active earning coaches declined to 16,100, while revenue per active coach rose to $4,664. The company established a $12.1M non-cash valuation allowance against deferred tax assets, which materially affected EPS.
Medifast provided 2026 revenue and EPS ranges and reinstated guidance as it executes a transformation toward metabolic health offerings.
Medifast (NYSE: MED) will announce financial results for the quarter and full year ended December 31, 2025, on Tuesday, February 17, 2026 after market close.
The company will host a conference call at 4:30 p.m. ET with CEO Dan Chard, President Nick Johnson, and CFO Jim Maloney. The call will be webcast and archived through May 17, 2026. Telephone and playback dial-in details are provided for listeners.
Medifast (NYSE: MED) highlighted Tiffany Howard’s metabolic health transformation with OPTAVIA after a People magazine feature on January 16, 2026. Tiffany credited OPTAVIA’s mix of science-backed nutrition, personalized coaching and community support for reversing metabolic dysfunction and achieving healthy weight loss while retaining lean mass.
The company cites a clinical study showing clients with OPTAVIA coaching achieved 10x greater weight loss, 17x more fat loss, 98% lean mass retention and a 14% reduction in visceral adiposity at 16 weeks. A commissioned survey found 94% of Americans worry about metabolic health and 85% believe reversal is possible.
Medifast (NYSE: MED) premiered the second episode of its OPTAVIA docuseries, “Health by Design: Spain”, which examines factors that support metabolic health and longevity in Galicia and Madrid. The episode, hosted by OPTAVIA co-founder Dr. Wayne Andersen and President Nicholas Johnson, highlights community, routine, activity, and diet as drivers of healthspan. The premiere was celebrated by thousands of independent coaches at Get America Healthy events on January 10, 2026.
Medifast (NYSE: MED) announced a planned leadership transition: Nicholas Johnson is appointed President effective immediately and is expected to succeed Dan Chard as Chief Executive Officer in June 2026. Dan Chard will remain Chairman of the Board after stepping down as CEO. The company said Johnson will work closely with Chard and the Board during a deliberate transition period. The announcement also notes that Tony Tyree, Chief Business Operations Officer, is leaving the company effective immediately. Johnson joined Medifast in 2018 and became Chief Field Operations Officer in 2022, having previously held leadership roles at Nu Skin.
Medifast (NYSE: MED) published OPTAVIA's report "Metabolic Health in America" (survey fielded Sep 23–29, 2025; n=1,004) showing 80% of U.S. adults lack understanding of metabolic health while 94% express concern about at least one related issue.
Key survey outcomes: 43% had heard the term, 65% report three+ metabolic concerns, 74% felt motivated to improve after learning the definition, and 85% believe metabolic dysfunction can be reversed. The release links these findings to Medifast's 2025 strategic shift to Metabolic Synchronization and cites a clinical study showing 14% visceral fat reduction and 98% lean mass retained at 16 weeks.